Literature DB >> 6315766

Serum immunoglobulin A antibody to varicella-zoster virus in subjects with primary varicella and herpes zoster infections and in immune subjects.

A E Wittek, A M Arvin, C M Koropchak.   

Abstract

Immunoglobulin A (IgA) antibodies to varicella-zoster virus (VZV) were measured in sera from subjects with acute varicella and herpes zoster, VZV-immune subjects remote from infection, and recipients of a live attenuated varicella vaccine, using a solid-phase radioimmunoassay. Primary infection with VZV was associated with early production of IgA antibodies. Among 36 subjects with varicella tested 1 to 5 days after onset, 22 had detectable IgA, and all of the negative sera were obtained before day 3 of the varicella exanthem. VZV IgA was detected in one of three sera obtained more than 60 days after onset of the illness. Four of five sera obtained from subjects within 1 week of the onset of herpes zoster had measurable levels of IgA. Between 1 and 4 weeks after onset of zoster, all 10 subjects tested had detectable IgA to VZV. VZV IgA was detected as late as 63 days after the onset of herpes zoster. Of 10 vaccine recipients, 5 developed VZV IgA which was detected as early as 4 weeks and persisted for as long as 16 weeks after vaccination. VZV IgA was not detected in sera from 42 children who had no detectable IgG antibody to VZV. VZV IgA was found on only 3 of 23 sera from adults who had varicella more than 20 years before.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6315766      PMCID: PMC272858          DOI: 10.1128/jcm.18.5.1146-1149.1983

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  16 in total

1.  Epstein-Barr virus-specific serum immunoglobulin A as an acute-phase antibody in infectious mononucleosis.

Authors:  J Nikoskelainen; E U Neel; D A Stevens
Journal:  J Clin Microbiol       Date:  1979-07       Impact factor: 5.948

2.  Varicella-Zoster Immunoglobulins during Varicella, Latency, and Zoster.

Authors:  P A Brunell; A A Gershon; S A Uduman; S Steinberg
Journal:  J Infect Dis       Date:  1975-07       Impact factor: 5.226

3.  Clinical and serologic testing of a live varicella vaccine and two-year follow-up for immunity of the vaccinated children.

Authors:  Y Asano; M Takahashi
Journal:  Pediatrics       Date:  1977-12       Impact factor: 7.124

Review 4.  Live attenuated Varicella-Zoster vaccine.

Authors:  A A Gershon
Journal:  Rev Infect Dis       Date:  1980 May-Jun

5.  The development and evaluation of a solid-phase radioimmunoassay (RIA) procedure for the determination of susceptibility to varicella.

Authors:  A Campbell-Benzie; H O Kangro; R B Heath
Journal:  J Virol Methods       Date:  1981-02       Impact factor: 2.014

6.  Application of live varicella vaccine to children with acute leukemia or other malignancies without suspension of anticancer therapy.

Authors:  K Ha; K Baba; T Ikeda; M Nishida; H Yabuuchi; M Takahashi
Journal:  Pediatrics       Date:  1980-02       Impact factor: 7.124

7.  Age-specific risks of varicella complications.

Authors:  S R Preblud
Journal:  Pediatrics       Date:  1981-07       Impact factor: 7.124

8.  IgA antibody response in acute rubella determined by solid-phase radioimmunoassay.

Authors:  P Halonen; O Meurman; M T Matikainen; E Torfason; H Bennich
Journal:  J Hyg (Lond)       Date:  1979-08

9.  Detection of specific IgA antibodies in serum of patients with varicella and zoster infections.

Authors:  E Levy; I Sarov
Journal:  Intervirology       Date:  1981       Impact factor: 1.763

10.  Immunoglobulins M and G to varicella-zoster virus measured by solid-phase radioimmunoassay: antibody responses to varicella and herpes zoster infections.

Authors:  A M Arvin; C M Koropchak
Journal:  J Clin Microbiol       Date:  1980-09       Impact factor: 5.948

View more
  6 in total

1.  Antibody-capture enzyme-linked immunosorbent assays that use enzyme-labelled antigen for detection of virus-specific immunoglobulin M, A and G in patients with varicella or herpes zoster.

Authors:  A M van Loon; J T van der Logt; F W Heessen; M C Heeren; J Zoll
Journal:  Epidemiol Infect       Date:  1992-02       Impact factor: 2.451

2.  Serologic detection of active infections with human herpes viruses (CMV, EBV, HSV, VZV): diagnostic potential of IgA class and IgG subclass-specific antibodies.

Authors:  H W Doerr; M Rentschler; G Scheifler
Journal:  Infection       Date:  1987 Mar-Apr       Impact factor: 3.553

3.  Virus-specific polymeric immunoglobulin A antibodies in serum from patients with rubella, measles, varicella, and herpes zoster virus infections.

Authors:  A Negro Ponzi; C Merlino; A Angeretti; R Penna
Journal:  J Clin Microbiol       Date:  1985-10       Impact factor: 5.948

Review 4.  Microbiology laboratory and the management of mother-child varicella-zoster virus infection.

Authors:  Massimo De Paschale; Pierangelo Clerici
Journal:  World J Virol       Date:  2016-08-12

5.  Herpes zoster: A clinicocytopathological insight.

Authors:  Snehal Shah; Sasidhar Singaraju; A Einstein; Ashish Sharma
Journal:  J Oral Maxillofac Pathol       Date:  2016 Sep-Dec

6.  Analysis of the Targets and Glycosylation of Monoclonal IgAs From MGUS and Myeloma Patients.

Authors:  Adrien Bosseboeuf; Célia Seillier; Nicolas Mennesson; Sophie Allain-Maillet; Maeva Fourny; Anne Tallet; Eric Piver; Philippe Lehours; Francis Mégraud; Laureline Berthelot; Jean Harb; Edith Bigot-Corbel; Sylvie Hermouet
Journal:  Front Immunol       Date:  2020-05-27       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.